Cite
Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor.
MLA
Fang, Qiyu, et al. “Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor.” Clinical Medicine Insights: Oncology, Nov. 2022, pp. 1–12. EBSCOhost, https://doi.org/10.1177/11795549221137134.
APA
Fang, Q., Yu, J., Luo, J., Deng, Q., Chen, B., He, Y., Zhang, J., & Zhou, C. (2022). Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor. Clinical Medicine Insights: Oncology, 1–12. https://doi.org/10.1177/11795549221137134
Chicago
Fang, Qiyu, Jia Yu, Jie Luo, Qinfang Deng, Bin Chen, Yayi He, Jie Zhang, and Caicun Zhou. 2022. “Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor.” Clinical Medicine Insights: Oncology, November, 1–12. doi:10.1177/11795549221137134.